Shutao Ma, Ph.D, Professor

PERSONAL DATA:
Professor of Medicinal Chemistry

Doctoral Supervisor

Director of Department of Medicinal Chemistry

Enjoyment of the Special government allowance from the State Council since 2002

The seventh youth awards of Shandong province

ADDRESS:
School of Pharmaceutical Sciences
Shandong University
No.44, Wenhuaxi Road, Jinan, 250012
P.R.China
Tel: 0086-531-8832009
Fax: 0086-531-8832009
E-mail: mashutao@sdu.edu.cn

EDUCATION:
2004--2007: Ph. D, School of Pharmaceutical Sciences, Shandong University
1988--1991: M. Sci., School of Pharmaceutical Sciences, Shandong Medical University
1981--1986: B. Sci., School of Pharmaceutical Sciences, Shandong Medical University

PROFESSIOAN EXPERIENCE:
2009--present: Professor, Director of Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University
2007--2008: Visiting scholar in Department of Chemistry, Vanderbilt University, United States
2003--2006: Professor, Director of Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University
1991--2002: Professor of Pharmacy, Director of Department of Pharmaceutical Synthesis, Shandong Institute of Pharmaceutical Industry
1986--1988: Pharmacist, Linyi Institute of Quality Control for Drugs, Shandong

RESEARCH INTERESTS:
1. Design, synthesis and activity of small molecules against resistant bacteria on the basis of drug targets such as FtsZ and AcrB.

2. Structural modification and structure-activity relationships of complicated structure antibiotics such as macrolides, glycopeptides and lipopeptides.

3. Total synthesis and mechanisms of antibacterial natural products such as marine macrolides.

HONORS, AWARDS AND RECOGNITIONS:
1. First prize of Shandong science and technology progress award (ranking first) in 2000, Certificate No. 00-1-9-1.

2. Special government allowance from the State Council in 2002, Certificate No. 03702010.

3. The seventh youth awards of Shandong province in 2002.

RESEARCH FOUNDING:
1. The National Natural Science Foundation of China, Grant No. 81673284, 2017.01–2020.12.

2. The National Natural Science Foundation of China, Grant No. 2107114, 2011.01–2013.12.

3. The National Natural Science Foundation of China, Grant No. 20872081, 2009.01–2011.12.

4. The National Natural Science Foundation of China, Grant No. 20372043, 2004.01–2006.12.

5. The National "Eleventh Five-Year", "Key New Drug Creation" Science and technology major projects, Grant No. 2009ZX09103-115, 2009.01–2011.12.

6. Shandong Provincial Natural Science Foundation, Grant No.ZR2015BM19, 2015.07–2017.07.

7. Shandong Provincial Natural Science Foundation, Grant No. ZR2010HM092, 2010.11–2013.11.

8. Shandong Provincial Natural Science Foundation, Grant No. Y2006C31, 2007.01–2009.12.

9. Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry (2010).

10. Shandong Provincial Science and Technology Projects, Grant No. 2005GG3202098, 2006.01–2008.12.

11. China–Australia Centre for Health Sciences Research, Grant No. CACHSR 2016GJ, 2016.01–2017.12.

12. China–Australia Centre for Health Sciences Research, Grant No. CACHSR 2016GJ06, 2014.01–2016.12.

RECENT PUBLICATION:
1. Li Jia, Shutao Ma*. Recent advances in the discovery of heparanase inhibitors as anticancer agents. Eur. J. Med. Chem. 2016, 121: 209–220.

2. Yinhu Wang, Henrietta Venter, Shutao Ma*. Efflux Pump inhibitors: A novel approach to combat efflux-mediated drug resistance in bacteria. Curr. Drug Targets 2016, 17: 702–719.

3. Di Song, Shutao Ma*. Recent development of benzimidazole-containing antibacterial agents. ChemMedChem 2016, 11, 646–659.

4. Shengsheng Qiang, Changde Wang, Henrietta Venter, Xin Li, Yi Wang, Liwei Guo, Ruixin Ma and Shutao Ma*. Synthesis and biological evaluation of novel FtsZ-targeted 3-arylalkoxy-2,6-difluorobenzamides as potential antimicrobial agents. Chem. Biol. Drug. Des. 2016, 87(2): 257–264.

5. Xin Li, Juzheng Sheng, Guihua Huang, Ruixin Ma, Fengxin Yin, Di Song, Can Zhao, Shutao Ma*. Design, synthesis and antibacterial activity of cinnamaldehyde derivatives as inhibitors of the bacterial cell division protein FtsZ. Eur. J. Med. Chem. 2015, 97: 32–47.

6. Yi Wang, Mi Yan, Ruixin Ma, Shutao Ma*. Synthesis and antibacterial activity of novel 4-bromo-1H-indazole derivatives as FtsZ inhibitors. Arch. Pharm. 2015, 348: 266–274.

7. Xin Li, Juzheng Sheng, Di Song, Liwei Guo, Shutao Ma*. Phenylacrylamides as novel FtsZ-targeted potential antimicrobials. Lett. Drug Des. Discov. 2015, 12(3): 234–240.

8. Mi Yan, Xiaodong Ma, Ruiqian Dong, Xin Li, Can Zhao, Zhenzhen Guo, Yan Shen, Fang Liu, Ruixin Ma, Shutao Ma*. Synthesis and antibacterial activity of 4"-O-(trans-β-arylacrylamido)carbamoyl azithromycin analogs. Eur. J. Med. Chem. 2015, 103: 506–515.

9. Xin Li, Shutao Ma*. Advances in the discovery of novel antimicrobials targeting the assembly of bacterial cell division protein FtsZ. Eur. J. Med. Chem. 2015, 95: 1–15.

10. Can Zhao, Yinhu Wang, Shutao Ma*. Recent advances on the synthesis of hepatitis C virus NS5B RNA-dependent RNA-polymerase inhibitors. Eur. J. Med. Chem. 2015, 102: 188–214.

11. Liwei Guo, Shutao Ma*. Advances in inhibitors of FXa. Curr. Drug Targets 2015, 16: 1207–1232.

12. Yan Shen, Shengsheng Qiang, Shutao Ma*. The Recent Development of Farnesyltransferase Inhibitors as Anticancer and Antimalarial Agents. Mini.Rev. Med. Chem. 2015, 15: 837–857.

13. Can Zhao, Shutao Ma*. Recent advances in the discovery of N-myristoyltransferase inhibitors. ChemMedChem 2014, 9: 2425–2437.

14. Zhenzhen Guo, Shutao Ma*. Recent advances in the discovery of metallo-lactamase inhibitors for β-lactam antibiotic-resistant reversing agents. Curr. Drug Targets 2014, 15: 689–702.

15. Yuanze Wang, Shutao Ma*. Small molecules modulating AHL-based quorum sensing to attenuate bacteria virulence and biofilms as promising antimicrobial drugs. Shutao Ma*. Curr. Med. Chem. 2014, 21, 296–311.

16. Siti Ma, Chao Cong, Xiaohui Meng, Shasha Cao, Hongkun Yang, Yuanyuan Guo, Xueyi Lu, Shutao Ma*. Synthesis and on-target antibacterial activity of novel 3-elongated arylalkoxybenzamide derivatives as inhibitors of the bacterial cell division protein FtsZ. Bioorg. Med. Chem. Lett. 2013, 23: 4076–4079.

17. Xin Li, Shutao Ma*. Recent developments in the discovery of Novel antipsychotic agents modualating dopamine and serotonin receptors. Curr. Drug Targets 2013, 14, 899–918.

18. Xin Li, Siti Ma, Mi Yan, Yuanze Wang, Shutao Ma*. Synthesis and antibacterial evaluation of novel 11,4²-disubstituted azithromycin analogs with greatly improved activity against erythromycin-resistant bacteria. Eur. J. Med. Chem. 2013, 59: 209–217.

19. Siti Ma, Rongmei Wang, Yuanze Wang, Jichao Cao, Shutao Ma*. The synthesis and antibacterial activity of novel 3-O-arylalkylbenzamide derivatives as FtsZ inhibitors. Lett. Drug Des. Discov. 2013, 10, 320–326.

20. Yi Wang, Shutao Ma*.Recent advances in inhibitors of bacterial fatty acid synthesis type II (FASII) system enzymes as potential antibacterial agents. ChemMedChem 2013, 8, 1589–1608.

21. Mi Yan, Shutao Ma*. Recent advances in the research of heterocyclic Compounds as antitubercular agents. ChemMedChem 2012, 7: 2063–2075.

22. Siti Ma, Shutao Ma*. The development of FtsZ inhibitors as potential antibacterial agents. ChemMedChem. 2012, 7: 1161–1172.

23. Mi Yan, Jichao Cao, Xin Li, Siti Ma, Yuanze Wang, Chao Cong, Shutao Ma*. Synthesis and antibacterial activity of novel 11-O-phenethylcarbamoylazithromycin derivatives with 4²-elongated side chains. Lett. Drug Des. Discov. 2012, 9: 833–839.

24. Sean M. DeGuire, Shutao Ma, Gary A. Sulikowski. Synthesis of a bicyclobutane fatty acid identified from the cyanobacterium anabaena PCC 7120. Angew. Chem. Int. Ed., 2011, 50: 9940–9942.

25. Xiaodong Ma, Ling Zhang, Rongmei Wang, Jichao Cao, Chen Liu, Yi Fang, Jida Wang, Shutao Ma*. Novel C-4² modified azithromycin analogs with remarkably enhanced activity against erythromycin-resistant Streptococcus pneumoniae: The synthesis and antimicrobial evaluation. Eur. J. Med. Chem. 2011, 46: 5196–5205.

26. Chao Cong, Haiyang Wang, Yue Hu, Chen Liu, Siti Ma, Xin Li, Jichao Cao, Shutao Ma*. Synthesis and antibacterial activity of novel 4²-O-benzimidazolyl clarithromycin derivatives. Eur. J. Med. Chem. 2011, 46: 3105–3111.

27. Shutao Ma*, Bo Jiao, Yongjing Ju, Manjie Zheng, Ruixin Ma, Lin Liu, Ling Zhang, Xuecui Shen, Chenchen Ma, Ya Meng, Hui Wang, Yunkun Qi, Xiaodong Ma, Wenping Cui. Synthesis and antibacterial evaluation of novel clarithromycin derivatives with C-4² elongated arylalkyl groups against macrolide-resistant strains. Eur. J. Med. Chem. 2011, 46: 556–566.

28. Ling Zhang, Bo Jiao, Xiangrui Yang, Lin Liu, Shutao Ma*. Synthesis and antibacterial activity of new 4²-O-carbamates of 11,12-cyclic carbonate erythromycin A 6,9-imino ether. J. Antibiot. 2011, 64: 243–247.

29. Yunkun Qi, Ruixin Ma, Xin Li, Yue Hu, Siti Ma, Chao Cong, Xiaodong Ma, Wenping Cui, Shutao Ma*. Novel clarithromycin analogs with C-4² 2-arylbenzimidazolyl bishydrazide side chain: synthesis and antibacterial evaluation. Lett. Drug Des. Discov. 2011, 8: 966–971.

30. Xiaodong Ma, Shutao Ma*. Significant breakthroughs in search for anti-infectious agents derived from erythromycin A. Curr. Med. Chem. 2011, 18: 1993–2015.

31. Yunkun Qi, Shutao Ma*. The medicinal potential of promising marine macrolides with anticancer activity. ChemMedChem 2011, 6: 399–409.

32. Wenping Cui, Shutao Ma*. Recent advances in the field of 16-membered macrolide antibiotics. Mini-Rev. Med. Chem. 2011, 11:1009–1018.

33. Ling Zhang, Linchen Song, Zhaopeng Liu, Hui Li, Yingdong Lu, Zerong Li, Shutao Ma*. Synthesis and antibacterial activity of novel 3-O-carbamoyl derivatives of clarithromycin and 11,12-cyclic carbonate azithromycin. Eur. J. Med. Chem. 2010, 45: 915–922.

34. Yongjing Ju, Ruiqing Xian, Ling Zhang, Ruixin Ma, Jichao Cao, Shutao Ma*. Synthesis and antibacterial activity of novel 4²-O-arylalkylcarbamoyl and 4²-O-((arylalkylamino)-4-oxo-butyl)arbamoyl clarithromycin derivatives. Bioorg. Med. Chem. Lett. 2010, 20: 3272–3274.

35. Yunkun Qi, Bo Jiao, Xiaodong Ma, Wenping Cui, Shutao Ma*. Synthesis and antibacterial activity of novel 4²-O-carbamoyl erythromycin A derivatives. Arch. Pharm. 2010, 8: 458–464.

36. Ling Zhang, Shutao Ma*. Efflux pump inhibitors–a strategy to combat P-glycoprotein and NorA multidrug resistant pump. ChemMedChem 2010, 5: 811–22.

37. Chenchen Ma, Shutao Ma*. Various novel erythromycin derivatives obtained by different modifications: recent advance in macrolide antibiotics. Mini-Rev. Med. Chem. 2010, 10: 272–286.

38. Chenchen Ma, Zhaopeng Liu, Hualing Song, Rentao Jiang, Fawen He, Shutao Ma*. Synthesis and antibacterial activity of novel 11,12-cyclic carbonate azithromycin 4²-O-carbamate derivatives. J. Antibiot. 2010, 63: 3–8.

39. Xuecui Shen, Bo Jiao, Shutao Ma*. Synthesis and antibacterial activity of 4²-O-carbamoyl analogs of clarithromycin. Chin. Chem. Lett. 2010, 21: 257–260.

40. Shutao Ma*, Ruixin Ma, Zhaopeng Liu, Chenchen Ma, Xuecui Shen. Synthesis and antibacterial activity of novel 15-membered macrolide derivatives: 4²-carbamate, 11,12-cyclic carbonate-4²-carbamate and 11,4²-di-O-arylcarbamoyl analogs of azithromycin. Eur. J. Med. Chem. 2009, 44: 4010–4020.

41. Shutao Ma*, Bo Jiao, Zhaopeng Liu, Hui Wang, Ruiqing Xian, Manjie Zheng, Hongxiang Lou. Synthesis and antibacterial activity of 4²,11-di-O-arylalkylcarbamoyl azithromycin derivatives that have activity against resistant strains, Bioorg. Med. Chem. Lett. 2009, 19: 1698–1701.

42. Shutao Ma*, Ruixin Ma, Ruiqing Xian, Bo Jiao. Synthesis of novel 15-membered macrolide dimers. Chin. Chem. Lett. 2009, 20: 931–934.